相关实验视频
Updated: Jun 27, 2025

07:54
Manipulation of Ploidy in Caenorhabditis elegans
Published on: March 15, 2018
11.0K
多重积分性促进多重转录,亡抵抗,在癌细胞和不同来源的介质细胞干细胞中的生:比较的转录组在研究研究
Olga V Anatskaya1, Alexander E Vinogradov1
1Institute of Cytology Russian Academy of Sciences, 194064 St. Petersburg, Russia.
International journal of molecular sciences
|April 27, 2024
概括
介质干细胞 (MSC) 中的多重积分不会导致癌症,但由于表观遗传变化,可能会损害它们的治疗潜力. 移除多倍体细胞可以改善MSC治疗.
科学领域:
- 细胞生物学 细胞生物学
- 遗传学 是一个遗传学.
- 生物技术是生物技术.
背景情况:
- 介质干细胞 (MSC) 显示出治疗前景,但在体外扩张过程中可以获得遗传和表观遗传改变.
- 多倍体性,即染色体组的增加,是影响MSC稳定性和功能的潜在因素.
研究的目的:
- 调查多聚性对MSC瘤安全性和治疗性质的影响.
- 为了比较MSC和癌细胞中多化诱导的转录组变化.
主要方法:
- 来自多倍体和双倍体癌细胞,MSC (骨髓,胎盘,心脏) 和诱导多能干细胞衍生的心肌细胞的转录数据的生物信息分析.
- 通过蛋白相互作用丰富分析 (PIEA) 识别持续诱导/抑制的基因和主调节体.
主要成果:
- 多重积分驱动细胞,包括MSC,向超转录,调高与家政功能,干性,DNA修复和染色体开放相关的基因.
- 激活中枢细胞维护和纤毛发育的途径,以及亡,昼夜钟和免疫路径的损害.
- 多聚合性并没有诱导瘤转化,但引起了全球表观遗传变化,并改变了MSC的基本生物过程.
结论:
- 多聚合性通过诱导显著的表观遗传变化和破坏基本的细胞功能来损害MSC的治疗性质.
- 研究结果表明,从MSC种群中消除多类细胞可以提高它们的治疗疗效.
相关概念视频
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
Cancers Originate from Somatic Mutations in a Single Cell
11.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.9K

